KINIKSA PHARMACEUTICALS INTERNATIO (KNSA)
Health Care · biotechnology · NASDAQ
Kiniksa is a biopharmaceutical company developing and commercializing therapies for chronic inflammatory and autoimmune diseases, with a pipeline featuring novel treatments for recurrent pericarditis.
What KINIKSA PHARMACEUTICALS INTERNATIO does
Kiniksa Pharmaceuticals is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients with chronic and debilitating inflammatory and autoimmune diseases. Its portfolio includes commercial products as well as a pipeline of drug candidates targeting recurrent pericarditis and other immunological conditions.
Themes: autoimmune diseases, inflammatory diseases, recurrent pericarditis, immunology, biopharmaceuticals
Fundamentals
- Price$80.20 as of 2026-08-25 close
- Market cap$6.1B as of 2026-08-26
- 1-year return+142.7% 2025-08-25 close $33.04 → 2026-08-25 close $80.20
- P/E75.29 as of 2026-08-26
- Net margin+9.6% as of 2026-08-26
- Gross margin+89.8% as of 2026-08-26
- ROE+13.7% as of 2026-08-26
- Debt / equity0.00 as of 2026-08-26
- Revenue growth (YoY)+58.9% as of 2026-08-26
- Revenue CAGR (3y)+45.5% SEC XBRL
- Beta0.03 as of 2026-08-26
- Last reported earnings2026-07-28 SEC EDGAR Form 8-K (Item 2.02)
How KNSA compares in its sector
- price-to-earnings ratiotop 25% 203 covered Health Care peers, as of 2026-08-26
- net profit margintop 25% 504 covered Health Care peers, as of 2026-08-26
- operating margintop 25% 504 covered Health Care peers, as of 2026-08-26
- gross margintop 25% 384 covered Health Care peers, as of 2026-08-26
- return on equitytop 25% 576 covered Health Care peers, as of 2026-08-26
- 3-year revenue CAGRtop 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)top 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
KNSA is in the Health Care Short-term Top 10.
Health Care Short-term Top 10 — since 24 Aug 2026
Long-term score
66.2 #113 of 1,608 scored · #11 of 198 in Health Care
Growth 97th (revenue growth year over year 58.9%, 3-year revenue CAGR 45.5%) and long-term trend 95th (trading above its 200-day average); weakest is capital return (18th, consecutive years of dividend increases 0 years).
Short-term score
66.1 #34 of 1,696 scored · #13 of 239 in Health Care
Trend 90th: a "golden cross" — its 50-day average is above its 200-day; catalysts 62nd: open-market insider buys in 90 days 31, the analyst consensus rating is unchanged since the prior reading; weakest is momentum 55th: mid-range on the stochastic oscillator. Its short interest was not measured, so no short-interest deduction applies.
In this list since 24 Aug 2026 — currently 6th in the list (1 days)
- Entered 24 Aug 2026: score 66.4, rank 8 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version).
Scores as of 25 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 3.
How KINIKSA PHARMACEUTICALS INTERNATIO looks technically
KINIKSA PHARMACEUTICALS INTERNATIO (KNSA) is trading 57.1% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 316 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 39, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 65, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 8 trading days ago (its momentum flipped negative). It made a new 20-day high about 20 trading days ago. It is 3.3% below its all-time high. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 9% of the past ~6 months), which often precedes a bigger move.
Trend
8
| Distance from the 200-day | it is trading 57.1% above its 200-day average, the long-term trend line — a longer-term uptrend | +57.1% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $68.15 | $68.15 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $51.05 | $51.05 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 27 calendar days ago — the swings before that are what the structure reading is measured on | 27 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 82.94. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a five-part sequence in leg 4. | possible three-wave upward correction, complete (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 316 trading days ago — a "golden cross", a bullish long-term signal | 316 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 39, with buyers in control | 38.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 65, neither overbought (above 70) nor oversold (below 30) | 64.6 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($75.00 to $81.57) — its "stochastic" reading is 79 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 79.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 8 trading days ago (its momentum flipped negative) | 8 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $82.94 | $82.94 |
|---|---|---|
| From the 52-week high | it is 3.3% below its 52-week high (its highest price of the past year) | -3.3% |
| Above the 52-week low | it is 143.8% above its 52-week low (its lowest price of the past year) | +143.8% |
| Below the 52-week high | it is 3.3% below its highest point of the past year | 3.3% |
| Since a 20-day breakout | it made a new 20-day high about 20 trading days ago | 20 sessions |
| Since a 55-day breakout | it made a new 55-day high about 20 trading days ago | 20 sessions |
| All-time high | its highest closing price on record is $82.94 (set on 2026-07-29) | $82.94 |
| Given back of the 52-week move | over the past year its closes ranged ($33.04 to $80.92), and it has given back essentially none of its rise from last year’s low — 2% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $49.80 to $51.33. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 1.5% |
| From the all-time high | it is 3.3% below its all-time high | -3.3% |
| Nearest price level | it is trading 40.6% above a support level at $47.65 — a price it turned at twice since 2026-03-04, most recently on 2026-03-16. Since 2024-08-26 it has 16 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -40.6% |
| All-time low | its lowest closing price on record is $5.01 (set on 2019-10-17) | $5.01 |
| Above the all-time low | it is 1500.8% above its all-time low | +1,501% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 9% of the past ~6 months), which often precedes a bigger move | 9th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.78 between its high and its low — about 3.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.78 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $73.96 and $81.75 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $73.96 – $77.86 – $81.75 |
| Typical daily range (% of price) | its price moves about 3.5% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.5% |
| Stretch from the 200-day average | it is trading 10.5 daily ranges above its 200-day average price (57.1% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 10.5 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.64× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|---|---|
| Since a bullish engulfing | today it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | today |
Price gaps
3
| Gap at the open | it opened on 2026-08-25 at essentially the same price it closed at the session before — no meaningful overnight gap | -0.0% |
|---|---|---|
| Open gap | it gapped 10.3% above the previous close 20 sessions ago and has not traded back through the level it left behind at 63.54 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +10.3% |
| Gap filled | a 2.4% gap up opened on 2026-08-04 has been "filled" 15 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 15 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 3 sessions in a row, a +2.2% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 3 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 24.0 percentage points (the stock gained 27.6% while the market gained 3.7%) | +24.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 47.9 percentage points (the stock gained 50.6% while the market gained 2.7%) | +47.9% |
| vs market, 6 months | over the past 6 months this stock beat the market by 77.1 percentage points (the stock gained 87.6% while the market gained 10.5%) | +77.1% |
| vs market, 12 months | over the past 12 months this stock beat the market by 123.5 percentage points (the stock gained 142.7% while the market gained 19.2%) | +123.5% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: MACD momentum is negative — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 32% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-20 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 5.2% of the share price. | +31.6% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 48% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $54.13 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +48.2% |
|---|---|---|
| Vs the average paid since it last reported | the price is 3% above the average price paid since it last reported on 2026-07-28 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $78.22 — a volume-weighted average of daily closes over 21 sessions, not a true tick-by-tick VWAP. | +2.5% |
Price levels it has turned at before
KNSA last closed at $80.20 on 2026-08-25. Since 2024-08-26 it has turned at 16 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $47.65 | Support | 40.6% below the last close | turned there twice · 2026-03-04 to 2026-03-16 |
| $45.80 | Support | 42.9% below the last close | turned there twice · 2026-02-03 to 2026-06-02 |
| $44.39 | Support | 44.6% below the last close | turned there three times · 2025-12-22 to 2026-04-09 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $82.94.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
Alternate reading: The same swings also read as a five-part sequence in leg 4, which fails on a close below $67.53.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-25.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · in a Bollinger Band volatility squeeze · in a strong, established uptrend (ADX) · Near the all-time high · beating the market · Printed a bullish engulfing pair | Learn: moving average · golden cross · adx · rsi · macd · breakout · all time high · bollinger bands
Based on daily closing prices as of 2026-08-25. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.13 mean, 1=Strong Buy…5=Strong Sell) — 8 analysts
- Mean price target$98.00 range $87.00 – $108.00; median $98.50
Analyst estimates, as of 2026-08-22. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for KNSA
- Consensus EPS estimate$0.315 next reporting period, as of 2026-08-22
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Reliance on the success of a limited number of product candidates and pipeline programs.","Risks associated with clinical trial outcomes, regulatory approvals, and the ability to compete in the highly competitive pharmaceutical market.","Dependency on commercial performance and potential delays in clinical development timelines for candidates like KPL-387 and KPL-1161."]
What changed in the latest 10-Q
AI-assisted comparison of KNSA's 10-Q filed 2026-04-28 against the prior one filed 2025-10-28.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-04-28) references risks updated in Part I, Item 1A of Annual Report as updated by Part II, Item 1A of subsequent Quarterly Reports
- Newer filing states Samsung Biologics Co., Ltd. was qualified as replacement CDMO and FDA accepted supplemental biologics license application in April 2026 with target action date of June 19, 2026
- Newer filing adds statement that KPL-387 'may expand the recurrent pericarditis market' and provides 'an additional treatment option for patients'
- Newer filing states expectation to initiate pivotal Phase 3 clinical trial of KPL-387 in recurrent pericarditis by end of 2026
- Newer filing states KPL-1161 preclinical activities expect Phase 1 first-in-human clinical trial by end of 2026
- Newer filing (2026-04-28) references audited consolidated financial statements for year ended December 31, 2025
- Removed:
- Older filing (2025-10-28) stated Samsung qualification was ongoing; newer filing confirms completion and FDA acceptance
- Older filing (2025-10-28) described KPL-387 as potentially 'help grow the market' and 'further advance' recurrent pericarditis treatment; newer filing uses different language about market expansion
- Older filing referenced Phase 1 clinical trial of KPL-387 initiated in June 2024 and plan to 'use totality of data to determine further development strategy' is new in 2026 filing
- Older filing (2025-10-28) stated KPL-1161 activities were 'IND-enabling activities'; newer filing states 'preclinical activities'
- Older filing included paragraph on Mavrilimumab asset with termination of license agreement and mutual termination with Huadong
- Older filing included details on Redomiciliation from Bermuda to United Kingdom incorporation completed in April 2024
- Older filing included financial metrics for nine months ended September 30, 2025 (net income of $44.8 million and accumulated deficit of $476.3 million) and cash position statement
- Reworded:
- Older filing referenced 'year ended December 31, 2024 included in our Annual Report on Form 10-K'; newer filing references 'year ended December 31, 2025 included in the Annual Report'
- Older filing referenced 'Part II-Item 1A Risk Factors section of this Quarterly Report'; newer filing references 'Part I, Item 1A of the Annual Report, as updated by any information appearing in Part II, Item 1A'
- KPL-387 description: older filing stated 'potentially enabling dosing with a single monthly subcutaneous self-injection'; newer filing states 'convenience of monthly subcutaneous self-administration'
- KPL-387 development language: older filing said 'We expect data from the Phase 2 portion of the trial in the second half of 2026'; newer filing added 'and plan to use the totality of the data to determine further development strategy'
- Notes:
- Older filing text appears truncated at end ('As of September 30, 2025, we had cash, cash equivalents and short-term invest'); comparison limited to complete portions
- Mavrilimumab and Redomiciliation content in older filing represents substantive business developments removed in newer filing but not necessarily contradicted by newer filing
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 1 open-market sale by insiders in the last 90 days.
- Last 30 days0 buys · 1 sell ($299092) — 1 selling insider
- Last 90 days0 buys · 1 sell ($299092) — 1 selling insider
- Last 180 days0 buys · 13 sells ($34M) — 6 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-29. As of 2026-08-26.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about KNSA's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Short interest (FINRA)
KNSA had 4,316,859 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
Short interest as a percent of shares outstanding is not shown for KNSA because we do not hold a verified share count to divide it by. The reported figures above are unaffected.
- Reported short interest (shares) 4,316,859
- Prior settlement (shares) 4,510,188
- Reported change -4.29%
- Days to cover (reported) 4.99
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Regeneron Pharmaceuticals (REGN)
- Amgen (AMGN)
- Novartis (NVS)
- Swedish Orphan Biovitrum (SOBI)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare KNSA vs…
KINIKSA PHARMACEUTICALS INTERNATIO is found in…
Frequently asked questions
What does KINIKSA PHARMACEUTICALS INTERNATIO (KNSA) do?
Kiniksa Pharmaceuticals is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients with chronic and debilitating inflammatory and autoimmune diseases. Its portfolio includes commercial products as well as a pipeline of drug candidates targeting recurrent pericarditis and other immunological conditions.
What sector is KINIKSA PHARMACEUTICALS INTERNATIO (KNSA) in?
KINIKSA PHARMACEUTICALS INTERNATIO (KNSA) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are KINIKSA PHARMACEUTICALS INTERNATIO's (KNSA) competitors?
Notable peers of KINIKSA PHARMACEUTICALS INTERNATIO (KNSA) include Regeneron Pharmaceuticals, Amgen, Novartis and Swedish Orphan Biovitrum. This peer set is informational only — not financial advice.
Is KINIKSA PHARMACEUTICALS INTERNATIO (KNSA) overbought or oversold right now?
KINIKSA PHARMACEUTICALS INTERNATIO (KNSA) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 65, in the neutral middle (as of 2026-08-25). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on KNSA come from?
Fundamentals and prices come from market data, as of 2026-08-26; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-26. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-25.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.